APA (7th ed.) Citation

Powles, T., Motzer, R., Escudier, B., Heng, D., Scheffold, C., Clary, D., & Choueiri, T. (2016). O4 - Patient outcomes based on prognostic risk groups in METEOR, a randomized phase 3 study of cabozantinib (cabo) versus everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC). European Urology Supplements, 15(13), e1546. https://doi.org/10.1016/S1569-9056(16)30377-3

Chicago Style (17th ed.) Citation

Powles, T., R.J Motzer, B. Escudier, D.Y.C Heng, C. Scheffold, D.O Clary, and T.K Choueiri. "O4 - Patient Outcomes Based on Prognostic Risk Groups in METEOR, a Randomized Phase 3 Study of Cabozantinib (cabo) Versus Everolimus (eve) in Patients (pts) with Advanced Renal Cell Carcinoma (RCC)." European Urology Supplements 15, no. 13 (2016): e1546. https://doi.org/10.1016/S1569-9056(16)30377-3.

MLA (9th ed.) Citation

Powles, T., et al. "O4 - Patient Outcomes Based on Prognostic Risk Groups in METEOR, a Randomized Phase 3 Study of Cabozantinib (cabo) Versus Everolimus (eve) in Patients (pts) with Advanced Renal Cell Carcinoma (RCC)." European Urology Supplements, vol. 15, no. 13, 2016, p. e1546, https://doi.org/10.1016/S1569-9056(16)30377-3.